Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: A pharmacogenetic study

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Caronia, Daniela ^a   Patiño Garcia, Ana ^b   Peréz Martínez, Antonio ^c   Pita, Guillermo ^a   Moreno, Leticia Tais ^a   Zalacain Díez, Marta ^b   Molina, Blanca ^c   Colmenero, Isabel ^c   Sierrasesúmaga, Luis ^b   Benítez, Javier ^a   Gonzalez Neira, Anna ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FOLINIC ACID; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PHARMACOGENETICS; PRESCHOOL CHILD; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; METHODOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OSTEOSARCOMA; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053897856     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026091     Document Type: Article

References (34)

1. Chou AJ, Gorlick R, (2006) Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther 6: 1075-1085.
2. Redlich G, Zanger UM, Riedmaier S, Bache N, Giessing AB, et al. (2008) Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry. J Proteome Res 7: 4678-4688.
3. Hayes JD, Pulford DJ, (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600.
4. Sissung TM, Gardner ER, Gao R, Figg WD, (2008) Pharmacogenetics of membrane transporters: a review of current approaches. Methods Mol Biol 448: 41-62.
5. Kindla J, Fromm MF, Konig J, (2009) In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol 5: 489-500.
6. Zhou SF, Di YM, Chan E, Du YM, Chow VD, et al. (2008) Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 9: 738-784.
7. Caronia D, Patino-Garcia A, Milne RL, Zalacain-Diez M, Pita G, et al. (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J 9: 347-353.
8. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, et al. (2003) Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97: 3068-3075.
9. Hosmer DW, Lemeshow S, (2000) Applied Logistic Regression. John Wiley & Sons, New York.
10. Hosmer DW, Lemeshow S, (1999) Applied Survival Analysis: regression modeling of time to event data. John Wiley & Sons, New York.
11. Lal S, Wong ZW, Sandanaraj E, Xiang X, Ang PC, et al. (2008) Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99: 816-823.
12. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Salagacka A, et al. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 25: 1167-1176.
13. Borst P, Evers R, Kool M, Wijnholds J, (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302.
14. Rost D, Konig J, Weiss G, Klar E, Stremmel W, et al. (2001) Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology 121: 1203-1208.
15. Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y, (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275: 2905-2910.
16. Zeng H, Liu G, Rea PA, Kruh GD, (2000) Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60: 4779-4784.
17. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P, (2001) Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276: 46400-46407.
18. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH, (2001) Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804.
19. Kobayashi K, Ito K, Takada T, Sugiyama Y, Suzuki H, (2008) Functional analysis of nonsynonymous single nucleotide polymorphism type ATP-binding cassette transmembrane transporter subfamily C member 3. Pharmacogenet Genomics 18: 823-833.
20. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, et al. (2004) Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14: 155-164.
21. Juranka PF, Zastawny RL, Ling V, (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3: 2583-2592.
22. Cascorbi I, Haenisch S Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 596: 95-121.
23. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
24. Morita N, Yasumori T, Nakayama K, (2003) Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65: 1843-1852.
25. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478.
26. Sakaeda T, (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20: 391-414.
27. Jamroziak K, Balcerczak E, Calka K, Piaskowski S, Urbanska-Rys H, et al. (2009) Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 33: 332-335.
28. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR, (2007) ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 7: 154-179.
29. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, et al. (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: 3246-3253.
30. Zhang YT, Yang LP, Shao H, Li KX, Sun CH, et al. (2008) ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients. Br J Clin Pharmacol 66: 240-246.
31. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, et al. (2009) A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20: 175-181.
32. Estrela Rde C, Ribeiro FS, Barroso PF, Tuyama M, Gregorio SP, et al. (2009) ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy. Pharmacogenomics 10: 311-318.
33. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, et al. (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27: 2604-2614.
34. Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR, (2006) Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol 71: 1695-1704.